Neurocrine Biosciences (NBIX) Amortization of Deferred Charges (2017 - 2021)
Historic Amortization of Deferred Charges for Neurocrine Biosciences (NBIX) over the last 5 years, with Q4 2021 value amounting to $300000.0.
- Neurocrine Biosciences' Amortization of Deferred Charges fell 2500.0% to $300000.0 in Q4 2021 from the same period last year, while for Dec 2021 it was $1.1 million, marking a year-over-year decrease of 2142.86%. This contributed to the annual value of $700000.0 for FY2023, which is 4166.67% down from last year.
- Per Neurocrine Biosciences' latest filing, its Amortization of Deferred Charges stood at $300000.0 for Q4 2021, which was down 2500.0% from $200000.0 recorded in Q3 2021.
- In the past 5 years, Neurocrine Biosciences' Amortization of Deferred Charges registered a high of $400000.0 during Q2 2019, and its lowest value of $200000.0 during Q3 2021.
- Its 5-year average for Amortization of Deferred Charges is $318315.8, with a median of $311000.0 in 2018.
- In the last 5 years, Neurocrine Biosciences' Amortization of Deferred Charges surged by 5893.72% in 2018 and then crashed by 3333.33% in 2021.
- Over the past 5 years, Neurocrine Biosciences' Amortization of Deferred Charges (Quarter) stood at $322000.0 in 2017, then fell by 3.42% to $311000.0 in 2018, then rose by 28.62% to $400000.0 in 2019, then changed by 0.0% to $400000.0 in 2020, then decreased by 25.0% to $300000.0 in 2021.
- Its last three reported values are $300000.0 in Q4 2021, $200000.0 for Q3 2021, and $300000.0 during Q2 2021.